mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

Costanza Bogani, Niccolò Bartalucci, Serena Martinelli, Lorenzo Tozzi, Paola Guglielmelli, Alberto Bosi, Alessandro M. Vannucchi, on behalf of the Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative

Abstract

Background: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patients with myelofibrosis but meaningful molecular responses were not documented. Accordingly, there remains a need for exploring new treatment strategies of MPN. A potential additional target for treatment is represented by the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway that has been found constitutively activated in MPN cells; proof-of-evidence of efficacy of the mTOR inhibitor RAD001 has been obtained recently in a Phase I/II trial in patients with myelofibrosis. The aim of the study was to characterize the effects in vitro of mTOR inhibitors, used alone and in combination with JAK2 inhibitors, against MPN cells.

Findings: Mouse and human JAK2V617F mutated cell lines and primary hematopoietic progenitors from MPN patients were challenged with an allosteric (RAD001) and an ATP-competitive (PP242) mTOR inhibitor and two JAK2 inhibitors (AZD1480 and ruxolitinib). mTOR inhibitors effectively reduced proliferation and colony formation of cell lines through a slowed cell division mediated by changes in cell cycle transition to the S-phase. mTOR inhibitors also impaired the proliferation and prevented colony formation from MPN hematopoietic progenitors at doses significantly lower than healthy controls. JAK2 inhibitors produced similar antiproliferative effects in MPN cell lines and primary cells but were more potent inducers of apoptosis, as also supported by differential effects on cyclinD1, PIM1 and BclXL expression levels. Co-treatment of mTOR inhibitor with JAK2 inhibitor resulted in synergistic activity against the proliferation of JAK2V617F mutated cell lines and significantly reduced erythropoietin-independent colony growth in patients with polycythemia vera.

Conclusions/Significance: These findings support mTOR inhibitors as novel potential drugs for the treatment of MPN and advocate for clinical trials exploiting the combination of mTOR and JAK2 inhibitor.

Introduction

The chronic myeloproliferative neoplasms (MPN), which include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) [1], are characterized by a V617F point mutation in the exon 14 of Janus Kinase 2 (JAK2) that occurs in 95% of PV and 60% of ET or PMF patients [2,3]. In addition, JAK2 exon 12 mutations are detected in 2–3% of PV [4] and mutations in MPL, the receptor for thrombopoietin, have been reported in 5–10% of ET and PMF patients [5–9]. These molecular abnormalities result in a constitutive activation of the JAK/signal transducer and activator of transcription (STAT) signaling pathway and contribute to cytokine hypersensitivity and cytokine independent growth of the mutant cells, as exemplified by the erythropoietin-independent erythroid colonies (EEC) typically found in most PV patients [9,10]. Transplant, transgenic and conditional knock-in murine models have shown that expression of mutated JAK2V617F is sufficient to recapitulate a MPN phenotype [11–19], indicating that constitutive activation of the JAK2/STAT pathway deserves a central role in the pathogenesis of MPNs.
Therefore, activated JAK2 has become an attractive target for therapy. In preclinical models, ATP-competitive JAK2 inhibitors prevented the proliferation of JAK2V617F mutant cells in vitro and mitigated myeloproliferation in JAK2V617F transgenic animals [20,21]. When employed in clinical trials, JAK2 inhibitors produced significant clinical improvement in patients with myelofibrosis [22,23] or hydroxyurea-resistant PV or ET [24] at such an extent that the JAK1 and JAK2 inhibitor ruxolitinib has been approved recently by FDA for the treatment of patients with intermediate and high risk myelofibrosis based on the results of two large phase III trials [25,26] demonstrating rapid and sustained reduction of splenomegaly and improvement of constitutional symptoms. However, only modest reduction of the JAK2V617F burden were documented [23]. This is consistent with the observation that the disease-initiating cell population in JAK2V617F knock-in mice was not affected by treatment with the JAK2 inhibitor TG101348 [12], supporting current notion that JAK2 mutation presumably does not represent the driver mutation in MPN [2,27]. Thus, it seems unlikely that eradication of the MPN clone can be achieved with (available) JAK2 inhibitors; therefore, novel drugs and more effective therapeutic strategies need to be sought. In this regard, it has been shown that treatment of the HDACi panobinostat and the JAK2 inhibitor TG101209 resulted in greater attenuation of JAK/STAT signaling in human and mouse JAK2V617F-mutated cells and increased cytotoxicity against MPN CD34+ cells compared to individual drugs [28].

Enhanced activation of downstream pathways other than JAK/STAT, including the phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) pathways, has been documented in JAK2V617F mutated cells [29,30]. The serine/threonine protein kinase B/Akt is downstream of PI3K [31]; it is a key regulator of many cellular processes including cell survival, proliferation and differentiation, and has been found dysregulated in many cancer cells [32]. The main target of activated Akt is the serine/threonine kinase mTOR that exists in two complexes, TORC1 and TORC2. TORC1, formed with raptor, controls the serine/threonine kinase mTOR itself and elongation-2 kinase. Both eIF4E and 4E (eIF4E), mTOR itself and elongation-2 kinase. Both eIF4E and 4E-BP are phosphorylated and activated via PI3K in response to signals originating by the erythropoietin (EPO) receptor; in particular, Akt is able to support erythroid differentiation in JAK2-deficient fetal liver progenitor cells through a mechanism downstream of EpoR [39] and at least in part related to GATA-1 phosphorylation [40]. Akt resulted strongly activated in erythroblasts from the bone marrow and the spleen of mice expressing a conditional JAK2V617F knock-in allele, especially in V617F homozygous animals [19]. Furthermore, phosphorylated STAT5 and Akt were found expresed high levels in the bone marrow of MPN patients, particularly in megakaryocytes [41], consistent with the strong inhibition of human megakaryocyte progenitors by rapamycin [42]. Finally, inhibitors of the JAK/STAT and PI3K/Akt pathway caused comparable inhibition of EEC formation and EPO-induced erythroid differentiation in cultured progenitor cells of patients with PV [43]. All this evidence is in favor of abnormal Akt/mTOR signaling in MPN cells and constitute the basis for exploring the potential effectiveness of drugs targeting this pathway in MPN cells.

In this study we evaluated the effects of mTOR inhibitors, either as single drugs or in combination with JAK2 inhibitors, in different cellular models and primary cells from patients with MPN. We present evidences that drugs targeting mTOR signaling exert significant inhibition of MPN cells and their activity is synergistically enhanced by co-treatment with a JAK2 inhibitor. Therefore, these results reinforce the pathogenetic role of disregulated Akt/mTOR pathway in MPNs and open new avenues for the treatments of these disorders.

Materials and Methods

Reagents

RAD001 (a mTOR specific allosteric inhibitor with activity against TORC1) was provided by Novartis (Basel, CH); PP242 [36] (an ATP domain inhibitor of mTOR, with activity against TORC1 and TORC2) was obtained from Sigma-Aldrich (St. Louis, Germany). The JAK1/JAK2 kinase ATP-competitive inhibitors AZD1152 (44) and INC124 (vuxotinib) were provided by D. Huszar (AstraZeneca, Waltham, MA, USA) and T. Radmieski (Novartis, Basel, CH), respectively. Antibodies against phospho-P-STAT5 (Tyr694), STAT5, P-4E-BP1 (Thr70), 4E-BP1, P-JAK2 (Tyr1007/1008) and JAK2 were from Cell Signaling Technology (Danvers, MA, US). Anti-human tubulin antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, US). Recombinant growth factors were purchased from Miltenyi Biotec (Gladbach, Germany).

Cell Lines and Cell Culture

The JAK2V617F mutated HEL and SET2 human cell lines were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Murine Ba/F3 and Ba/F3-EPOR cells expressing JAK2 wild-type (wt) or JAK2V617F (VF) were donated by R. Skoda (University of Basel, Switzerland) [45]. Cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS; Lonza, Belgium) (20% for SET2 cells), antibiotics and L-glutamine. Recombinant human EPO (rhEPO; Sigma) was added to JAK2 wt Ba/F3-EPOR cells, that require the cytokine for survival and proliferation, at final concentration of 1 U/mL. This concentration was chosen based on preliminary experiments showing that this amount of cytokine, in addition to support cell proliferation and survival (%90% of cells were routinely viable in the cultures),

PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e54826
mTOR Inhibitors in Myeloproliferative Neoplasms

A

- **Ba/F3-EPOR wt**
- **Ba/F3-EPOR V617F**

Viability vs. Concentration for:
- RAD001 (μM)
- AZD1480 (μM)
- PP242 (μM)
- Ruxolitinib (μM)

B

- **RAD001 (μM)**
- **AZD1480 (μM)**
- **PP242 (μM)**
- **Ruxolitinib (μM)**

Colony formation vs. Concentration for:
- RAD001 (μM)
- AZD1480 (μM)
- PP242 (μM)
- Ruxolitinib (μM)
promoted phosphorylation of STAT5 at such an extent that was very close to that measured in cultures of Ba/F3-EPOR VF cells maintained in a cytokine-free medium (Figure S1).

**Human Cells**

Samples of peripheral blood or bone marrow were obtained from patients diagnosed with PV or PMF (2008 WHO criteria) [46] under a protocol approved by Institutional Review Board of Azienda Ospedaliera-Universitaria Careggi and after obtaining a written informed consent; CD34+ cells were immunomagnetically selected as described [47]. Control CD34+ cells were obtained from discarded cord blood units. Research was carried out according to the principles of Declaration of Helsinki.

**Inhibition of Proliferation Assay, Clonogenic Assay, and Apoptosis or Cell Cycle Analysis**

Ba/F3-EPOR cells, both wt and VF, HEL and SET2 cells were plated at 2 x 10^5 in 96-well culture tissue plates with increasing concentrations of the drug(s), in triplicate, and the amount of viable cells was assessed at 48 h using the WST-1 assay (Roche, USA) after normalization to wells containing an equivalent volume of vehicle (DMSO) only. For clonogenic assay, 5 x 10^3 cells were plated in 0.5% agar in medium supplemented with 10% FBS (plus 1 U/mL EPO in case of Ba/F3-EPOR wt cells); variable amount of the drug(s) (or an equivalent volume of vehicle in control plates) was added once at the beginning of culture. Colonies were enumerated by inverted microscopy after 7 day incubation, in independent experiments. Individual IC50 values were reported in the Results section. 

Table 1. Effects of mTOR (RAD001 and PP242) and JAK2 (Ruxolitinib and AZD1480) inhibitors on the proliferation rate and clonogenic growth of human JAK2V617F mutated cell lines.

| IC50 (µM) | Proliferation assay | Clonogenic assay |
|-----------|---------------------|-----------------|
|           | RAD001   | PP242   | AZD1480 | Ruxolitinib |
| HEL       | 1.4±0.2 | 1.5±0.1** | 0.86±0.02** | 0.79±0.15** |
| SET2      | 1.7±0.3 | 0.28±0.01* | 0.09±0.05** | 0.16±0.02** |

DNA Isolation and Real-Time Quantitative PCR (RTQ-PCR)

Total RNA was purified using Trizol (Invitrogen-Life Technologies, Paisley, UK), and the RNA concentration and purity/integrity was determined with NanoDrop ND-1000 spectrophotometer (NanoDrop Techn., Wilmington, DE, USA). One microgram of RNA was reverse transcribed using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). RT-QPCR reactions were performed with the TaqMan Universal PCR Master Mix using ABI PRISM 7300 HT and TaqMan® Gene Expression Assays (Applied Biosystems), in triplicate. Gene expression profiling was achieved using the Comparative cycle threshold (Ct) method of relative quantitation using VIC-labeled RnaseP probe as the housekeeping gene (ΔCt).

**Figure 1. Inhibition of cell proliferation and colony formation of wild-type (wt) and JAK2V617F (VF)-expressing Ba/F3-EPOR cells by mTOR and JAK2 inhibitors.** Results of short-term proliferation assay (panel A) and clonogenic assay (panel B) are shown. Values represent the percent inhibition compared to control wells containing vehicle only. Data shown are the mean of at least five (panel A) and three (panel B) independent experiments. Individual IC50 values are reported in the Results section.

doi:10.1371/journal.pone.0054826.g001

doi:10.1371/journal.pone.0054826.t001
**Statistical Methods**

Comparison between groups was performed by the Mann-Whitney U or Fisher test as appropriate, using the SPSS (StatSoft, Inc., Tulsa, OK) or Origin software. The level of significance from two-sided tests was $P<0.05$.

**Results**

Inhibition of mTOR Signaling Results in Reduced Proliferation and Impaired Colony Formation of JAK2V617F Mutant Cell Lines

To ascertain the effects of mTOR inhibition on the growth of cell lines harboring the JAK2V617F mutation we employed the selective allosteric mTOR inhibitor RAD001 and the ATP competitive inhibitor of the active site of mTOR, PP242. Concurrently, we used the two ATP-competitive JAK2 inhibitors ruxolitinib and AZD1480. JAK2 wt Ba/F3 cells engineered to express the erythropoietin receptor (Ba/F3-EPOR wt) and the cytokine-independent counterpart with ectopic expression of $JAK2^{V617F}$ (Ba/F3-EPOR VF) were exposed to increasing drug concentrations in proliferation (48 h; Figure 1A) and clonogenic (7 days; Figure 1B) assay. We found that Ba/F3-EPOR VF cells were definitely more sensitive to inhibition of the mTOR pathway than the wt counterpart: the IC$_{50}$ (mean±SD) was 651±50 nM versus 11,000±1,000 nM and 500±100 nM versus 5,931±1,000 nM, respectively, in case of RAD001 and PP242 ($P<0.001$ for both) (Figure 1A). Similarly, JAK2 inhibitors effectively prevented the growth of Ba/F3 VF cells with greater sensitivity compared to wt cells; the IC$_{50}$ was 313±23 nM versus 752±30 nM and 220±20 nM versus 457±15 nM in case of AZD1480 and Ruxolitinib, respectively ($P<0.001$ for both) (Figure 1A). Also the clonogenic potential of Ba/F3-EPOR VF cells, evaluated in semisolid cultures, was potently inhibited by mTOR and JAK2 inhibitors at very low nanomolar concentrations, as shown in
Efficacy of the drugs was also assessed in the human JAK2V617F mutated HEL and SET2 cell lines. We found that both cell lines were relatively insensitive to RAD001 showing an IC50 in the micromolar range (mean value, 14.0 μM and 17.0 μM, respectively for HEL and SET2 cells), unlike the case of PP242 and JAK2 inhibitors that efficaciously prevented cell proliferation at nanomolar concentration (see Table 1). On the other hand, counterintuitively, colony formation by HEL and SET2 cells was efficaciously prevented at nanomolar concentrations of RAD001 (mean value, 0.93 nM and 0.044 nM for HEL and SET2 cells, respectively) and PP242 (0.172 nM and 0.062 nM), and similar for JAK2 inhibitor AZD1480 (0.46 nM and 0.035 nM) and Ruxolitinib (0.37 nM and 0.027 nM) (Table 1). We are not able to provide obvious explanations for such contrasting findings concerning the efficacy of RAD001 in clonogenic versus proliferation assay, that could not be actually ascribed to different culture conditions, variable times of drug exposure, types of plastics used as well as a number of other variables we deliberately introduced in the system. One possibility might be that optimal inhibition of HEL and SET2 cell proliferation by RAD001 requires some kind of cell-to-cell interactions that are favoured in the semisolid media as compared with liquid cultures. These experiments also indicated that HEL cells, that display multiple copies of JAK2V617F, resulted significantly less sensitive than the JAK2V617F heterozygous SET2 cells.

In further experiments aimed at evaluating the effects of treatment on cell cycle and apoptosis we used SET2 cells as a model. Mirroring the results obtained in Ba/F3-EPOR VF cells, we observed a dose-dependent decrease of SET2 cells in the S-phase due to a block in G0/G1: a 50% reduction of SET2 cells in the S-phase compared to controls was obtained with a median concentration of 33 μM for RAD001, 2.7 μM for PP242, 1.5 μM for AZD1480 and 10 μM for Ruxolitinib. Apoptosis was promoted more efficaciously by JAK2 inhibitors (median IC50 values for apoptosis were 0.4 μM for AZD1480 and 0.5 μM for Ruxolitinib) than RAD001 (38 μM) and PP242 (5.2 μM) (data not shown in detail).

Inhibition of the mTOR- and JAK2-dependent signalling pathways in Ba/F3-EPOR and SET2 cells exposed to the relevant drugs was supported by results of western blot experiments showing reduced levels of phosphorylated 4eBPI, in case of mTOR inhibitors, and phosphorylated JAK2 and STAT3 in case of JAK2 inhibitors (Figure S3A, B). We also assayed the mRNA level of selected downstream targets in SET2 cells. We found that mTOR and JAK2 inhibitors similarly induced statistically significant early downregulation of CCND1, that however resulted more durable (at 24 h) with JAK2 inhibitors. On the other hand, JAK2 inhibitors only caused a statistically significant downregulation of antiapoptotic genes such as PUM1 and BCL XL (Figure S4).

As a whole, these data indicate that blocking mTOR signalling pathway is effective in reducing proliferation and clonogenic potential of cells expressing the JAK2V617F mutation; however, mTOR inhibitors appeared to exert mainly a cytostatic rather than an apoptotic effect when compared with JAK2 inhibitors.

### mTOR Inhibitors Impair the Proliferation and Clonogenic Potential of CD34+ Cells from MPN Patients

To exploit whether the proliferation of primary MPN cells could be similarly affected by mTOR inhibitors, we incubated CD34+ cells from PMF patients and healthy controls (n = 6 and n = 5, respectively) with increasing concentration of RAD001 and PP242, and measured the proportion of viable cells relative to control wells containing vehicle only; an optimized cytokine cocktail was added to both patients’ and controls’ wells to allow

---

**Table 2.** Activity of mTOR (RAD001 and PP242) and JAK2 (Ruxolitinib and AZD1480) inhibitors on the clonogenic potential of hematopoietic progenitors from patients with PV and PMF (n = 10 each) and healthy controls (n = 10).

| IC50 (nM) | RAD001 | PP242 | AZD1480 | Ruxolitinib |
|-----------|---------|-------|---------|-------------|
| BFU-E     |         |       |         |             |
| Ctrl      | 432±22  | 233±50| 226±17  | 167±70      |
| PV        | 91±15**,| 58±18*| 135±19**| 27±7*       |
| MF        | 42±10**,| 38±8* | 27±8**  | 46±10*      |

*The IC50 was calculated using data derived from the sensitivity curves to drugs reported in Figure 3.*

---

Figure 1B. The IC50 for VF and wt Ba/F3-EPOR cells was 4±2 nM versus 22±10 nM and 47±12 nM versus 308±100 nM for RAD001 and PP242, respectively, and 19±11 nM versus 750±100 nM and 20±15 nM versus 740±100 nM for AZD1480 and ruxolitinib, respectively (P<0.01 for all combinations). Similar results were obtained using the parental IL-3- dependent Ba/F3 JAK2 wt and VF cell lines (not shown). Finally, we tested the effect of different inhibitors also in liquid cultures of cytokine-independent Ba/F3 VF cells maintained in the presence of Epo (1 U/mL). We found that the IC50 remained significantly lower (>100 nM for RAD001 11 nM for AZD1480 and 521 nM for Ruxolitinib, respectively) and PP242 (0.172 nM and 0.062 nM), and similar for JAK2 inhibitor AZD1480 (0.46 nM and 0.035 nM) and Ruxolitinib (0.37 nM and 0.027 nM) (Table 1). We are not able to provide obvious explanations for such contrasting findings concerning the efficacy of RAD001 in clonogenic versus proliferation assay, that could not be actually ascribed to different culture conditions, variable times of drug exposure, types of plastics used as well as a number of other variables we deliberately introduced in the system. One possibility might be that optimal inhibition of HEL and SET2 cell proliferation by RAD001 requires some kind of cell-to-cell interactions that are favoured in the semisolid media as compared with liquid cultures. These experiments also indicated that HEL cells, that display multiple copies of JAK2V617F, resulted significantly less sensitive than the JAK2V617F heterozygous SET2 cells.

In further experiments aimed at evaluating the effects of treatment on cell cycle and apoptosis we used SET2 cells as a model. Mirroring the results obtained in Ba/F3-EPOR VF cells, we observed a dose-dependent decrease of SET2 cells in the S-phase due to a block in G0/G1: a 50% reduction of SET2 cells in the S-phase compared to controls was obtained with a median concentration of 33 μM for RAD001, 2.7 μM for PP242, 1.5 μM for AZD1480 and 10 μM for Ruxolitinib. Apoptosis was promoted more efficaciously by JAK2 inhibitors (median IC50 values for apoptosis were 0.4 μM for AZD1480 and 0.5 μM for Ruxolitinib) than RAD001 (38 μM) and PP242 (5.2 μM) (data not shown in detail).

Inhibition of the mTOR- and JAK2-dependent signalling pathways in Ba/F3-EPOR and SET2 cells exposed to the relevant drugs was supported by results of western blot experiments showing reduced levels of phosphorylated 4eBPI, in case of mTOR inhibitors, and phosphorylated JAK2 and STAT3 in case of JAK2 inhibitors (Figure S3A, B). We also assayed the mRNA level of selected downstream targets in SET2 cells. We found that mTOR and JAK2 inhibitors similarly induced statistically significant early downregulation of CCND1, that however resulted more durable (at 24 h) with JAK2 inhibitors. On the other hand, JAK2 inhibitors only caused a statistically significant downregulation of antiapoptotic genes such as PUM1 and BCL XL (Figure S4).

As a whole, these data indicate that blocking mTOR signalling pathway is effective in reducing proliferation and clonogenic potential of cells expressing the JAK2V617F mutation; however, mTOR inhibitors appeared to exert mainly a cytostatic rather than an apoptotic effect when compared with JAK2 inhibitors.

mTOR Inhibitors Impair the Proliferation and Clonogenic Potential of CD34+ Cells from MPN Patients

To exploit whether the proliferation of primary MPN cells could be similarly affected by mTOR inhibitors, we incubated CD34+ cells from PMF patients and healthy controls (n = 6 and n = 5, respectively) with increasing concentration of RAD001 and PP242, and measured the proportion of viable cells relative to control wells containing vehicle only; an optimized cytokine cocktail was added to both patients’ and controls’ wells to allow
cell survival. As shown in Figure 2, the proliferation of PMF CD34+ cells was inhibited at significantly lower concentration of RAD001 (IC50 = 271 ± 100 nM) and PP242 (IC50 = 800 ± 200 nM) compared to healthy subjects (IC50 = 5,000 nM and 2,900 ± 1,000 nM, respectively (P<0.01 for both). Similarly AZD1480 and ruxolitinib produced more effective inhibition of the proliferation rate of CD34+ cells from PMF patients (IC50 = 474 ± 50 nM and 840 ± 300 nM, respectively) compared to control cells (IC50 = 891 ± 100 nM and >5,000 nM; P<0.05 and 0.001, respectively).

Then, to evaluate the effects of mTOR inhibitors on the colony-forming activity of hematopoietic progenitors from MPN patients, bone marrow mononuclear cells or CD34+ cells from PMF and PV patients and healthy controls were cultured in the presence of cytokines optimally supporting the growth of BFU-E, CFU-G/M, or CFU-Mk. Increasing amounts of mTOR inhibitors (RAD001 and PP242) or JAK2 inhibitors (AZD1480 and Ruxolitinib) were added at the beginning of culture. Colonies were enumerated on day 14 and expressed as a percentage of the colonies grown in control plates containing vehicle only.

Figure 3. mTOR and JAK2 inhibitors preferentially suppress colony formation from hematopoietic progenitors of MPN patients as compared to healthy controls. Mononuclear cells from patients with PV or PMF (n = 10 each) or control subjects (n = 10) were plated at 10^6/mL in cytokine-supplemented methylcellulose medium for the growth of erythroid burst-forming unit (BFU-E) and granulocyte-macrophage colony-forming unit (CFU-GM), and CD34+ cells (5 x 10^5/mL) were plated in collagen-based medium for megakaryocyte colony-forming unit (CFU-Mk). Increasing amounts of mTOR inhibitors (RAD001 and PP242) or JAK2 inhibitors (AZD1480 and Ruxolitinib) were added at the beginning of culture. doi:10.1371/journal.pone.0054826.g003
dishes containing vehicle only. As shown in Figure 3, colony formation from MPN patients was dose-dependently reduced by mTOR inhibitors; the data reported in Table 2 indicate that MPN progenitor growth could be inhibited with IC50 drug concentration significantly lower than control cells (in case of RAD001, from 4.7 to 13-fold lower and in case of PP242 from 2.6 to 6.1-fold lower, depending on colony type), pointing to a substantial degree of drug selectivity against MPN cells. Progenitors forming megakaryocytic colonies were the most sensitive. Results obtained with JAK2 inhibitors were similar, with IC50 values lower than control of 1.6–21.4-fold in case of AZD1480 and 3–6.2-fold in case of Ruxolitinib. By keeping separate JAK2 V617F positive and negative PMF subjects (n = 5 each) we did not observe appreciable difference in the inhibitory effect of either drugs depending on the JAK2 mutation status of the patients (not shown in detail). Finally, we determined that the growth of EEC from circulating progenitors in PV patients (n = 5) could be inhibited at very low nanomolar concentrations of RAD001 (IC50 = 15.0 ± 10.0 nM),

| Single drug | Drug combination | IC50 (nM) | IC50 (nM) | CI index |
|-------------|-----------------|---------|---------|---------|
| RAD001      | AZD1480         | 651 ± 50| 313 ± 23| 0.5 ± 0.1|
|             | Ruxolitinib     | 651 ± 50| 220 ± 20| 0.3 ± 0.1|
| PP242       | AZD1480         | 500 ± 100| 313 ± 23| 0.5 ± 0.2|
|             | Ruxolitinib     | 500 ± 100| 220 ± 20| 0.79 ± 0.3|
| SET2        | RAD001          | 17,000 ± 3,000| 90 ± 5| 0.48 ± 0.05|
|             | Ruxolitinib     | 17,000 ± 3,000| 160 ± 24| 0.66 ± 0.05|
|             | AZD1480         | 285 ± 11| 90 ± 5| 0.56 ± 0.1|
|             | Ruxolitinib     | 285 ± 11| 160 ± 24| 0.27 ± 0.2|
| Ba/F3-EPOR VF | RAD001         | 4 ± 2| 19 ± 11| 0.4 ± 0.3|
|             | Ruxolitinib     | 4 ± 2| 20 ± 15| 0.6 ± 0.3|
|             | AZD1480         | 500 ± 100| 19 ± 11| 0.8 ± 0.2|
|             | Ruxolitinib     | 500 ± 100| 20 ± 15| 0.24 ± 0.2|
| SET2        | RAD001          | 44 ± 15| 35 ± 10| 0.23 ± 0.1|
|             | Ruxolitinib     | 44 ± 15| 27 ± 9| 0.32 ± 0.04|
|             | AZD1480         | 62 ± 19| 35 ± 10| 0.4 ± 0.05|
|             | Ruxolitinib     | 62 ± 19| 27 ± 9| 0.9 ± 0.13|

Data shown (mean ± SD) are from at least two experiments. The Combination Index (CI) was calculated as described in Materials and Methods. A CI <1 indicates that the interaction of the two drugs is synergistic. The first two columns report, for convenience, the IC50 value of the individual drugs in these experimental settings (see Results section for details). doi:10.1371/journal.pone.0054826.t003
Table 4. Combination of mTOR and JAK2 inhibitor resulted synergistic in reducing erythropoietin-independent colony formation in primary cells from PV patients.

| Drug combination | IC50 (nM) | IC50 (nM) | CI index |
|------------------|-----------|-----------|----------|
| RAD001 AZD1480   | 15±10     | 19±2      | 2.9±2    |
| RAD001 AZD1480   | 25±1      |           | 0.61±0.2 |
| Ruxolitinib RAD001 | 15±10     | 1.8±1     | 1.9      |
| RAD001 Ruxolitinib |     | 0.2       | 0.26     |
| PP242 AZD1480    | 1±0.7     | 19±2      | 0.04     |
| PP242 AZD1480    | 0.7       | 0.7       | 0.13     |
| PP242 Ruxolitinib | 1±0.7     | 1.8±1     | 0.16±0.1 |
| PP242 Ruxolitinib | 0.3       | 0.2       | 0.5±0.3  |

Data shown (mean ± SD) are derived from the analysis of two patients, in duplicate. The Combination Index (CI) was calculated as described in Materials and Methods. A CI<1 indicates that the combination of the two drugs is synergistic. The first two columns (in gray) report, for convenience, the IC50 value of the individual drugs in this experimental setting (see Results section for details).

doi:10.1371/journal.pone.0054826.t004

PP242 [IC50 = 1.0±0.7 nM], AZD1480 [IC50 = 19.0±2.0 nM] and Ruxolitinib [IC50 = 1.8±1.0 nM], indicating a high sensitivity of these progenitors, that are considered as being mostly with V617 mutated [10,49], to both mTOR and JAK2 inhibitors.

In aggregate, these data indicate that colony growth from hematopoietic progenitors of MPN patients can be efficiently and selectively inhibited by mTOR inhibitors compared to controls.

Combination of mTOR and JAK2 Inhibitor Results in Improved Efficacy Against MPN Cells

Next, we evaluated the effects of concurrent inhibition of mTOR and JAK2 signaling in Ba/F3-EPOR VF and SET2 cells. Cells were put in culture using progressively increasing concentrations of the drugs and the proportion of viable cells at 48 h, or the number of colony formed at 10d, was measured; the combination index (CI), as a measure of the interaction between two drugs, was calculated as detailed in the Methods section (examples are shown in Figure S5 and 6). Results presented in Table 3 indicate that combination of a mTOR and JAK2 inhibitor resulted in markedly lower concentrations of the individual drugs necessary to produce a 50% inhibition in the assay. For example, the proliferation of SET2 cells could be efficaciously inhibited with RAD001 amounts of 9.4 to 10.6-fold lower, 2.3 to 7.9-fold in case of PP242, 3.1 to 9.4-fold in case of AZD1480 and 3.0 to 5.1-fold in case of Ruxolitinib, depending on the drug combinations. The calculated CI values was always lower than 1, ranging from 0.33 to 0.98, to indicate synergism of the mTOR and JAK2 inhibitors in the two cell lines and experimental settings.

We finally assessed the efficacy of combining mTOR and JAK2 inhibitor in preventing the generation of EEC from peripheral blood mononuclear cells of PV patients. As reported in Table 4, the concentration of mTOR and JAK2 inhibitors required to produce a 50% inhibition of EEC were reduced, as compared to each drug alone, of 5.2 to 7.9-fold in case of RAD001, 2.5 to 6.2-fold in case of PP242, 7.6 to 27-fold in case of AZD1480 and 6 to 9-fold in case of Ruxolitinib. The calculated CI ranged from 0.13 to 0.63.

Therefore, these results strongly support synergism of mTOR and JAK2 inhibitors in inhibiting the growth of MPN cells.

Discussion

Dysregulation of the JAK2/STAT pathway represents a central mechanism in the pathogenesis of MPNs: in fact, (i) the JAK2V617F gain-of-function mutation occurs in the majority of patients with PV and 60% of PMF and essential thrombocythemia [2,3], (ii) other mutations (MPL, LNK, CBL) found in 5–10% can similarly activate the JAK/STAT pathway [5-8,30], (iii) mouse models indicate that those mutations are able to induce a myeloproliferative disorder [11–19], (iv) the JAK/STAT pathway is involved in the dysregulated cytokine expression that accompanies MPNs and underlies some tract of the clinical phenotype [51], and finally (v) targeting activated JAK2 with ATP-competitive JAK2 inhibitors resulted in measurable clinical improvements in patients with myelofibrosis [25,26]. The clinical efficacy of JAK2 inhibitors has been ascribed to a variable degree of myelosuppression and a general down-regulation of inflammatory cytokine signalling (at least in part mediated by the concomitant anti-JAK1 properties of some JAK2 inhibitors such as ruxolitinib) [52], well keeping in mind that none of the available molecules is specific to mutant as opposed to wild-type JAK2. Conceivably, in contrast to the capacity of JAK2 inhibitors to reduce the enlarged spleen and improve disease symptomatic manifestations, changes in the burden of mutated cells have been variable (with SAR302503 being reported as the most effective until now [53]) but usually modest, at least in the short-term follow-up. Also, while generally well tolerated, JAK2 inhibitors caused some degree of unwanted myelosuppression, particularly anemia and thrombocytopenia.

Therefore, current efforts are directed towards additional targets involved in the dysregulated proliferation of MPN cells and/or novel therapeutic options with the hope to maximize anticancer efficacy and/or improve the tolerability profile of available JAK2 inhibitors.

In this study we have focused on the mammalian target of rapamycin (mTOR), a key downstream target of the PI3K/Akt pathway, with the objective to characterize the efficacy of mTOR inhibitors in different cellular models of MPNs, including primary cells. We found that JAK2V617F mutated human and murine leukemia cell lines are sensitive to mTOR inhibitors showing a dose-dependent inhibition of cell proliferation and clonogenic potential that mainly reflected a cytostatic rather than an apoptotic effect. However, the ATP mimetic inhibitor PP242 resulted a more potent and dose-dependent inducer of apoptosis than the allosteric inhibitor RAD001, leading to speculate that such a difference may be attributable to the activity of PP242 against both mTORC complexes as opposed to the inhibition of mTORC1 only exerted by RAD001 [31]; further experiments are in progress at this regard. We also showed that mTOR inhibitors inhibited the proliferation of CD34+ cells and hematopoietic colony formation from MPN patients at doses significantly lower than healthy subjects and potently reduced the generation of erythroid-independent colonies (EEC) that are considered to closely represent the MPN clone since they are mostly JAK2V617F mutated [10,49]. As a whole, these results, indicating sensitivity of MPN cells to mTOR inhibitors, provided mechanistic explanation for the findings of a phase I/II trial that showed efficacy of RAD001 (Everolimus) against splenomegaly and symptomatic burden in patients with myelofibrosis [54] and reinforce the rationale for designing clinical trials with novel, and possibly more effective, drugs targeting the activated PI3K/Akt/mTOR pathway.

In fact, the abnormal activation of mTOR in cancer cells and its role in many critical cellular processes, together with the availability of a growing number of molecules entering the clinical
scenario, makes it an attractive target for therapy in neoplasia where involvement of the mTOR pathway contributes to disease pathogenesis; activation of this pathway has been demonstrated in MPN cells [29,30], JAK2V617F-expressing mice [19] [30] and primary samples [41,43]. However, in most trials performed in different clinical settings [35] RAD001 and other rapalogs resulted in disease stabilization rather than tumor regression, an effect largely attributable to the predominantly cytostatic effect of these agents. Indeed, in a mouse myeloproliferative disease model characterized by constitutively active STAT5, treatment with rapamycin effectively reduced myeloid cell proliferation in transplanted mice and significantly prolonged survival; however, the myeloproliferative disease recurred once the treatment was stopped [56]. Such prevalent antiproliferative rather than pro-apoptotic effect of rapamycin derivatives including RAD001 has prompted on one side studies of combination with agents that preferentially induce apoptosis or are directed against other disease-associated targets [55] on the other the development of novel ATP-competitive mTOR inhibitors or dual PI3K/mTOR inhibitors. Bearing this in mind, we explored the effects of combining mTOR and JAK1/JAK2 inhibitors in vitro. We first determined that, in the same experimental settings, JAK2 inhibitors (AZD1480 [44] and Ruxolitinib [21]) efficaciously impaired the growth of JAK2V617F mutated mouse and human cell lines and primary cells by slowing the progression to S-phase of the cell cycle and exerting a more definite apoptotic effect, at least in part mediated by downregulation of BclXL and PIM. Accordingly, we determined that combination of mTOR and JAK2 inhibitor resulted in significant synergism concerning the inhibition of proliferation and colony formation of mouse and human JAK2V617F mutated leukemia cell lines and prevented at very low nanomolar concentration the formation of EPO-independent erythroid colonies. Combinations of mTOR inhibitor with chemotherapeutics, targeted drugs or antibodies are being explored in preclinical models and/or have been preliminary reported in clinical trials. At this regard, combination of rapamycin with ABT-737, an inhibitor of Beclin1, has recently been shown to provoke synergistic effects in mice with a myeloproliferative disorder due to constitutively active STAT5 and persistent activation of Akt/mTOR signalling [57]. Present data describing synergistic activity of mTOR- and JAK/STAT1-directed therapies in cellular models of MPN foresee the opportunity of testing this association in clinical trials, with the expectation that such combination might results in a better therapeutic index producing more effective inhibition of clonal cells and also, due to the modest toxicity of mTOR inhibitors against normal cells, by reducing unwanted side effects of JAK2 inhibitors administered at lower, yet effective, dose.

Supporting Information

Figure S1 Effect of different amount of EPO added to the culture medium of Ba/F3-EPOR wild-type cells on the level of phosphorylated STAT5. In order to determine the optimal amount of EPO that induced phosphorylation of STAT5 in Ba/F3-EPOR wild-type (wt) cells at level comparable with JAK2V617F (VF) mutated cells, we added different amounts of EPO and then processed the cells for western blot analysis after 6 h. Each phosphoSTAT5 band was first normalized by densitometric analysis using the ImageQuant 350 apparatus (GE Healthcare, Little Chalfont, UK) and the ImageQuant 5.2 software against corresponding total STAT5, then the values measured in wt cells were normalized against the level measured in V617F cells considered as = 1. The amount of phosphoSTAT5 in the presence of 1 U/mL Epo was 1.2, close to VF cells. (TIF)

Figure S2 Effect of mTOR (RAD001 and PP242) and JAK2 (AZD1480 and Ruxolitinib) inhibitors on apoptosis and cell cycle in Ba/F3-EPOR VF cells. In panel A, the frequency of cells in the G0/G1, S and M phase of the cell cycle was measured by flow cytometry after propidium iodide staining of Ba/F3-EPOR VF cells that had been exposed to the drugs for 18 h, and expressed as percent change compared to control cells (Cttl) with vehicle. Results shown are the Mean±SD of at least three experiments. In panel B, the percentage of Annexin V-positive cells was measured in cultures of Ba/F3-EPOR VF cells exposed to varying amount of the drugs for 48 h; percentage was calculated after subtraction of background apoptosis in cells incubated without drug. Results shown are the Mean±SD of at least three experiments. (TIF)

Figure S3 Effect of mTOR (RAD001 and PP242) and JAK2 (AZD1480 and Ruxolitinib) inhibitors on key targets in Ba/F3-EPOR VF and SET-2 cells. A. JAK2 wt and VF Ba/F3-EPOR cells were incubated for 6 h with final concentrations of the drugs corresponding to the IC50 values measured in proliferation assay (see Results for details). B. SET-2 cells were incubated for 24 h with increasing concentrations of the drugs, as indicated. The level of total and phosphorylated JAK2, STAT5, and 4EBP1 was analyzed by western blot. Tubulin was used for loading normalization. One representative of two to four similar experiments. (TIF)

Figure S4 Effect of mTOR (RAD001 and PP242) and JAK2 (AZD1480 and Ruxolitinib) inhibitors on the expression of selected downstream molecules in SET-2 cells. The expression level of mRNA for PIM1, BclXL and CCND1 was measured by RTQ-PCR in SET-2 cells at different times of incubation with the IC50 concentration of each drug, in triplicate. Gene expression profiling was achieved using the Comparative cycle threshold (CT) method of relative quantitation using VIC-labeled RNaseP probe as PIM1 the housekeeping gene (ACT). Where not indicated, SD was <10% for each experimental point and was not depicted. This experiment has been repeated twice with similar results. *, P<0.05; **, P<0.01. (TIF)

Figure S5 Analysis of the combinatorial effects of mTOR (RAD001 and PP242) and JAK2 (AZD1480 and Ruxolitinib) inhibitors in Ba/F3-EPOR VF cells. Cells were evaluated in proliferation assay for 48 h using WST-1 assay to measure the proportion of cells alive, after subtraction of the value measured in control wells with vehicle only. “Fa” is the cell fraction affected by the dose of the drug; the combination Index (CI) was calculated as described in Materials and Methods using Calcsyn Software. A CI<1 indicates that the interaction of the two drugs is synergistic. (TIF)

Figure S6 Analysis of the combinatorial effects of mTOR (RAD001 and PP242) and JAK2 (AZD1480 and Ruxolitinib) inhibitors in SET-2 cells. Cells were evaluated in proliferation assay for 48 h using WST-1 assay to measure the proportion of cells alive, after subtraction of the value measured in control wells with vehicle only. “Fa” is the cell fraction affected by the dose of the drug; the combination Index (CI) was calculated as...
described in Materials and Methods using Calcusyn Software. A CI<1 indicates that the interaction of the two drugs is synergistic. (TH)

Acknowledgments
We thank R. Skoda, Dr. D. Huszar and Dr. T. Radimerski for generously providing vital reagents and for helpful suggestions.

References
1. Vannucci AM, Guglielmelli P, Tefferi A (2009) Advances in understanding and management of myeloproliferative neoplasms. AC- A Cancer Journal for Clinicians 59: 171–191. 18. Vainchenker W, Delhommeau F, Constantinouc SN, Bernard OA (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118: 1729–1735. 19. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, et al. (2010) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673–683. 20. Scott LM, Tong W, Levine RL, Bench AJ, Erber WN, et al. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112: 141–149. 21. Vannucci AM, Antonioli E, Guglielmelli P, Pancrazi A, Guerrini V, et al. (2008) Characteristics and clinical correlates of MPL 5135N/VLK mutation in essential thrombocythemia. Blood 112: 844–847. 22. Pardanani A, Guglielmelli P, Lasho TL, Pancrazi A, Finke CM, et al. (2010) Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 663 patients. Leukemia 24: 1834–1839. 23. Pichal JF, Ausralad AA (1974) Letter: Bone-marrow responses in polycythemia vera and idiopathic erythrosclerosis. N Engl J Med 296: 459–460. 24. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, et al. (2006) JAK2V617F is described in Materials and Methods using Calcusyn Software. A

Author Contributions
Conceived and designed the experiments: CB NB AMV. Performed the experiments: CB NB SM LT PG. Analyzed the data: CB NB LT PG AB AMV. Wrote the paper: CB NB LT PG AMV.
recommendations from an ad hoc international expert panel. Blood 110: 1092–1097.

47. Vannucchi AM, Pancrazzi A, Guglielmelli P, Di Lollo S, Bogani C, et al. (2005) Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol 167: 849–858.

48. Chou T-C (2010) Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research 70: 440–446.

49. Nussenzeig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, et al. (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35: 32–38.

50. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182–6192.

51. Tefferi A, Vaidya R, Caramazza D, Finke C, Laslo T, et al. (2011) Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. J Clin Oncol 29: 1356–1363.

52. Tefferi A (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119: 2721–2730.

53. Pardanani A, Gotlib J, Jamieson C, Cortes J, Talpaz M, et al. (2008) A phase I study of TG101346, an orally bioavailable JAK-selective inhibitor, in patients with myelofibrosis. Blood 112: 97.

54. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, et al. (2011) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 118: 2069–2076.

55. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278–2297.

56. Li G, Wang Z, Miskimen KL, Xie XY, Tse W (2009) Genetic and pharmacologic targeting of STAT5/Gab2/PI3K/mTOR signaling in a mouse myeloproliferative disease model. Blood 114: 3962A.

57. Li G, Miskimen KL, Wang Z, Xie XY, Tse W, et al. (2010) Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 24: 1397–1405.